New collaboration aims to advance innovation for a neglected and stigmatizing disease affecting hundreds of thousands worldwide NEW YORK (January
New York, USA and Manila, Philippines — [Date] — TB Alliance and the Asian Development Bank (ADB) have announced a
Positive results mark an important step forward in efforts to develop effective treatments for children with drug-resistant TB COPENHAGEN, Denmark
Thuto Pulane, a TB survivor and participant in the NC-009 trial, at a follow-up appointment with Dr. William Brumskine, NC-009
Four years ago, TB Alliance secured the first regulatory approval from the United States Food and Drug Administration (US FDA)
NEW YORK (March 23, 2021) – Interested researchers are invited to apply to access the MARK-TB (Markedly Accelerating Research with
November 13, 2019 – Results of the Phase 2B trial, known as NC-005 have been published in The Lancet Respiratory Medicine.
The Stop TB Partnership’s Global Drug Facility (GDF) has added the anti-TB drug pretomanid to its catalog of TB medicines.
NEW YORK and MUMBAI (October 28, 2019)—Non-profit drug developer TB Alliance has granted Macleods Pharmaceuticals Limited a non-exclusive license to
The public health progress in the World Health Organization’s Global Tuberculosis (TB) Report 2019 this year can be found in
